The ocular distribution of ¹⁴C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model

References

• BucoloCMelilliBPiazzaCZurriaMDragoFOcular pharmacokinetics profile of different indomethacin topical formulationsJ Ocul Pharmacol Ther201127657157622059858
   PubMed Web of Science ®Google Scholar
• RenfroLSnowJSOcular effects of topical and systemic steroidsDermatol Clin19921035055121617809
   PubMed Web of Science ®Google Scholar
• BeckerBThe side effects of corticosteroidsInvest Ophthalmol1964349249714229934
   PubMedGoogle Scholar
• McGheeCNPharmacokinetics of ophthalmic corticosteroidsBr J Ophthalmol1992766816841477046
   PubMed Web of Science ®Google Scholar
• MiyanagaMMiyaiTNejimaRMaruyamaYMiyataKKatoSEffect of bromfenac ophthalmic solution on ocular inflammation following cataract surgeryActa Ophthalmol200987330030519183412
   PubMed Web of Science ®Google Scholar
• Prolensa^® [package insert]Tampa, FLBausch + Lomb2013
   Google Scholar
• AhujaMDhakeASSharmaSKMajumdarDKTopical ocular delivery of NSAIDsAAPS J200810222924118437583
   PubMed Web of Science ®Google Scholar
• Guex-CrosierYNon-steroidal anti-inflammatory drugs and ocular inflammationKlin Monbl Augenheilkd20012185305308 French11417322
   PubMed Web of Science ®Google Scholar
• GluudBSJensenOLKroghEBirgensHSProstaglandin E2 level in tears during postoperative inflammation of the eyeActa Ophthalmol (Copenh)19856343753793863452
   PubMed Web of Science ®Google Scholar
• OkaTShearerTAzumaMInvolvement of cyclooxygenase-2 in rat models of conjunctivitisCurr Eye Res2004291273415370364
   PubMed Web of Science ®Google Scholar
• MiyamotoTSaikaSOkadaYExpression of cyclooxygenase-2 in corneal cells after photorefractive keratectomy and laser in situ keratomileusis in rabbitsJ Cataract Refract Surg200430122612261715617933
   PubMed Web of Science ®Google Scholar
• RadiZARenderJAThe pathophysiologic role of cyclo-oxygenases in the eyeJ Ocul Pharmacol Ther200824214115118355129
   PubMed Web of Science ®Google Scholar
• WalshDAMoranHWShambleeDAAntiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analoguesJ Med Chem19842711137913886436487
   PubMed Web of Science ®Google Scholar
• YanniJMGraffGHellbergMRinventorsAlcon Laboratories Inc., assigneeAdminstering 3-benzoylphenylacetamide derivatives United States patent US547503419951212
   Google Scholar
• RuizJLópezMMilàJLozoyaELozanoJJPouplanaRQSAR and conformational analysis of the antiinflammatory agent amfenac and analoguesJ Comput Aided Mol Des1993721831988320556
   PubMed Web of Science ®Google Scholar
• WaterburyLDSillimanDJolasTComparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodiumCurr Med Res Opin20062261133114016846546
   PubMed Web of Science ®Google Scholar
• BucoloCMarrazzoGPlataniaCBRomanoGLDragoFSalomoneSEffects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammationJ Pharm Pharmacol201466795496024697218
   PubMed Web of Science ®Google Scholar
• MiyakeKOgawaTTajikaTGowJAMcNamaraTROcular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humorJ Ocul Pharmacol Ther200824657357819049295
   PubMed Web of Science ®Google Scholar
• BaklayanGAPattersonHMSongCKGowJAMcNamaraTR24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbitsJ Ocul Pharmacol Ther200824439239818665811
   PubMed Web of Science ®Google Scholar
• KidaTOgawaTMcNamaraTRSongCKGowJAEvaluation of the human Cox-2 inhibition of amfenac, bromfenac, diclofenac, and ketorolacProceedings of the Annual American Society of Cataract and Refractive Surgery ConferenceApril 27 – May 2, 2007San Diego, CA
   Google Scholar
• UedaKOhtoriATojoKEffects of pathological conditions on ocular pharmacokinetics of antimicrobial drugsChem Pharm Bull (Tokyo)201058101301130520930394
   PubMed Web of Science ®Google Scholar
• ChoHMozayanANew look at ocular inflammation control – powerful and fast-acting twice-daily bromfenac for a novel standard in the treatment of inflammationEuropean Ophthalmic Review2011512026
   Google Scholar
• O’BrienTPEmerging guidelines for the use of NSAID therapy to optimize cataract surgery patient careCurr Med Res Opin20052171131113716004683
   PubMed Web of Science ®Google Scholar
• JonesJFrancisPOphthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agentExpert Opin Pharmacother200910142379238519735215
   PubMed Web of Science ®Google Scholar
• CarreñoEPorteroAGalarretaDJHerrerasJMUpdate on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extractionClin Ophthalmol2012663764422570544
   PubMedGoogle Scholar
• CableMComparison of bromfenac 0.09% QD to nepafenac 0.1% TID after cataract surgery: pilot evaluation of visual acuity, macular volume, and retinal thickness at a single siteClin Ophthalmol20126997100422815642
   PubMedGoogle Scholar
• WarrenKABahraniHFoxJENSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edemaRetina20103026026620175270
   PubMed Web of Science ®Google Scholar
• RadwanAEArcinueCAYangPArtornsombudhPAbu Al-FadlEMFosterCSBromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edemaGraefes Arch Clin Exp Ophthalmol20132511801180623519884
   PubMed Web of Science ®Google Scholar
• EndoNKatoSHaruyamaKShojiMKitanoSEfficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetesActa Ophthalmol201088889690019725815
   PubMed Web of Science ®Google Scholar
• WangQWYaoKXuWBromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsificationOphthalmologica2013229418719423429038
   PubMed Web of Science ®Google Scholar
• GomiFSawaMTsujikawaMNishidaKTopical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degenerationRetina2012321804181022718152
   PubMed Web of Science ®Google Scholar
• FlaxelCSchainMBHamonSCFrancisPJProspective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot studyRetina20123241742321862953
   PubMed Web of Science ®Google Scholar
• ZweifelSAEngelbertMKhanSFreundKBRetrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degenerationRetina2009291527153119898185
   PubMed Web of Science ®Google Scholar